NFE2L2 and lung carcinoma: In 995 lung cancer cases, 423 cases were estimated to have constitutive NRF2 activation, and 165 cases harbored either NRF2 or KEAP1 mutations with higher expression of NRF2 target genes, including Aldo-Keto Reductase Family 1 Member B10 (AKR1B10), Aldo-Keto Reductase Family 1 Member B15 (AKR1B15), Glutathione Peroxidase 2 (GPX2), Thioredoxin Reductase 1 (TXNRD1), Glutamate-Cysteine Ligase Modifier Subunit (GCLM), and Glutamate-Cysteine Ligase Catalytic Subunit Glutamate-Cysteine Ligase Catalytic Subunit (GCLC) [21].